Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGB1 | P09429 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17058837 | 0.85 | ALDH1A1 (0.41) | HMGB1KMT2AALDH1A1FOLH1TSHR | |
| SCHEMBL9331010 | 0.81 | HMGB1 (0.53) | HMGB1TAAR1KMT2AALDH1A1FOLH1 | |
| SCHEMBL10276952 | 0.80 | CLCN2 (0.43) | KMT2AALDH1A1HTR2ATSHRPOLB | |
| SCHEMBL11397191 | 0.80 | TSHR (0.43) | KMT2AALDH1A1FOLH1LMNATSHR | |
| SCHEMBL13601942 | 0.80 | KEAP1 (0.47) | KMT2AALDH1A1FOLH1LMNA | |
| SCHEMBL31484803 | 0.79 | HMGB1 (0.70) | HMGB1TAAR1ALDH1A1FOLH1HTR2A | |
| SCHEMBL1449563 | 0.79 | HMGB1 (0.70) | HMGB1TAAR1ALDH1A1FOLH1HTR2A | |
| SCHEMBL731621 | 0.79 | HMGB1 (0.55) | HMGB1TAAR1KMT2AALDH1A1FOLH1 | |
| SCHEMBL10308375 | 0.77 | PDK2 (0.46) | KMT2AALDH1A1TSHRPDK2 | |
| SCHEMBL17058852 | 0.77 | HMGB1 (0.43) | HMGB1TAAR1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200291086-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | Han, Jie (US) | 2020-09-17 | — | — | US | disclosed |
| US-10626156-B2 | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs | Han, Jie (US) | 2020-04-21 | — | — | US | disclosed |
| US-20150246958-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | BAIKANG (SUZHOU) CO., LTD (CN) | 2015-09-03 | — | — | US | disclosed |
| US-5008452-A | Antidepressants, sedatives and anticonvulsants | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1991-04-16 | — | — | US | disclosed |
| US-4235931-A | ANTIDEPRESSANTS | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1980-11-25 | — | — | US | disclosed |
| US-4192818-A | ANTIDEPRESSANTS | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1980-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626156-B2 | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs | NOS2, EGLN2, HPGD | HMGB1 535/4885TAAR1 1916/4885KMT2A 3057/4885 |
| US-20150246958-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | HMGB1 535/4885TAAR1 1916/4885KMT2A 3057/4885 |
| US-20200291086-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | HMGB1 535/4885TAAR1 1916/4885KMT2A 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.